INTRODUCTION

The standard curative treatment for gastric cancer (GC) in East Asia is gastrectomy with D2 lymphadenectomy.1,2 To date, however, it remains unclear whether the East Asian approach to gastrectomy with lymphadenectomy is feasible and safe in Western patients and whether it is reproducible in terms of mortality and morbidity. Thus, in the present study, we examined a series of Caucasian patients (CPs) subjected to gastrectomy at a single institution with the intent of addressing this issue from the point of view of both surgeon-related and patient-related factors.

CASE REPORT

Between June 2011 and April 2014, 12 CPs underwent gastrectomy for gastric cancer at Yonsei University Severance Hospital, Seoul, Korea. In all patients, tumor depth, nodal status, and disease stage were classified in accordance with the American Joint Committee on Cancer Staging (7th edition).3

When Eastern Surgeons Meet Western Patients:
A Pilot Study of Gastrectomy with Lymphadenectomy in Caucasian Patients at a Single Korean Institute

Masatoshi Nakagawa1,2*, Yoon Young Choi1*, Ji Yeong An1, Sang Hyuk Seo1, Hyun Beak Shin1, Hui-Jae Bang1, Shuangxi Li1,3, Hyung-II Kim1, Jae-Ho Cheong1, Woo Jin Hyung1, and Sung Hoon Noh1,4

1Department of Surgery and 1Brain Korea 21 PLUS Project for Medical Science, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea; 2Department of Gastric Surgery, Tokyo Medical and Dental University, Tokyo, Japan; 3Department of Gastrointestinal Surgery, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China. East Asian surgeons generally report lower morbidity and mortality rates for gastrectomy with D2 lymphadenectomy than do surgeons in Western countries; however, the disparity remains unexplained. The aim of this article was to determine the feasibility and safety regarding cases in which East Asian surgeons perform such procedures in Caucasian patients (CPs). Twelve CPs underwent gastrectomy with lymphadenectomy for gastric cancer at Yonsei University Severance Hospital, Seoul, Korea between June 2011 and April 2014. Procedures performed included total gastrectomy (7 of 12, 58%), distal gastrectomy (4 of 12, 33%), and completion total gastrectomy (1 of 12, 8%). Nine patients (75%) underwent D2 lymphadenectomy, and D1+ lymphadenectomy was performed in three others (25%). In four patients (33%), combined resections were carried out. The median values of surgical parameters were as follows: operative time, 266.5 min (range, 120–586 min); estimated blood loss, 90 mL (range, 37–350 mL); retrieved lymph node count, 37.5 (range, 22–63); and postoperative hospital stay, 13.7 days (range, 5–63 days). No mortality was encountered, although two patients (17%) experienced complications (both Clavien-Dindo classification grade IIIa anastomotic leakages), which were successfully managed by conservative treatment. In the hands of East Asian surgeons, mortality and short-term morbidity appears to be acceptably low in CPs subjected to gastrectomy with lymphadenectomy for gastric cancer.

Key Words:
Gastric cancer, gastrectomy, lymphadenectomy, Caucasians

INTRODUCTION

The standard curative treatment for gastric cancer (GC) in East Asia is gastrectomy with D2 lymphadenectomy.1,2 To date, however, it remains unclear whether the East Asian approach to gastrectomy with lymphadenectomy is feasible and safe in Western patients and whether it is reproducible in terms of mortality and morbidity. Thus, in the present study, we examined a series of Caucasian patients (CPs) subjected to gastrectomy with lymphadenectomy at a single institution with the intent of addressing this issue from the point of view of both surgeon-related and patient-related factors.

CASE REPORT

Between June 2011 and April 2014, 12 CPs underwent gastrectomy for GC at Yonsei University Severance Hospital, Seoul, Korea. In all patients, tumor depth, nodal status, and disease stage were classified in accordance with the American Joint Committee on Cancer Staging (7th edition).3 Based on the Jap-
Japanese Gastric Cancer Treatment Guidelines (3rd edition), the extent of each lymphadenectomy was also stipulated.

Complication data were prospectively evaluated according to the Clavien-Dindo Classification. Major complications corresponded with grade IIIa or greater. All surgeons at our institute had performed more than 200 gastrectomies with D2 lymphadenectomy procedures prior to the current cohort and perform over 150 gastrectomies for GC annually. This project was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Yonsei University Severance Hospital (4-2014-0499).

Baseline characteristics and perioperative results of all patients are summarized in Table 1, and pathological characteristics of each patient are shown in Tables 2 and 3. The median age of CPs (males, 8; females, 4) was 62.5 years (range, 40–71 years), with a median body mass index of 24.8 kg/m² (range, 18.6–45.9 kg/m²). The native countries of CPs were as follows: Russia, 7; the United States, 2; Ukraine, 2; and Kazakhstan, 1. All were considered medical tourists, defined as non-resident travelers to Korea for GC treatment. Minimally invasive surgery was performed in six CPs (50%). The types of procedures performed included total gastrectomy (7 of 12, 58%), distal gastrectomy (4 of 12, 33%), and completion total gastrectomy (1 of 12, 8%). Nine patients (75%) underwent D2 lymphadenectomy, with the remaining three (25%) undergoing D1+ dissections. Combined resection was performed in four patients (33%): one cholecystectomy for gallbladder stone, one partial colectomy for direct tumor invasion of the transverse colon, one thyroidectomy for thyroid cancer, and one thymectomy for thymoma. Median values of surgical parameters were as follows: operative time, 266.5 min (range, 120–586 min); estimated blood loss, 90 mL (range, 37–350 mL); retrieved lymph node count, 37.5 (range, 22–63); and postoperative hospital stay, 8 days (range, 5–63 days). No mortality occurred, although two patients (17%) developed anastomotic leakages (both Clavien-Dindo classification grade IIIa).

**DISCUSSION**

To our knowledge, the present article is the first patient series addressing short-term results when East Asian surgeons performed gastrectomy with lymphadenectomy in CPs. Our findings suggest that acceptable short-term outcomes are achievable in CPs through standard East Asian procedures.

Although the clinicopathological characteristics of our cohort did approximate those of previously reported Western studies (albeit a younger age range in the current study), current morbidity and mortality rates were lower than those of the earlier Western reports (morbidity, 23.6–46%; mortality, 2–13%).

---

Table 1. Baseline Characteristics and Perioperative Results of Enrolled Patients

| Variable                                      | Caucasian patients (n=12) |
|-----------------------------------------------|--------------------------|
| Age (median, range) (yrs)                     | 62.5 (40–71)             |
| BMI (median, range) (kg/m²)                   | 24.8 (18.6–45.9)         |
| Sex                                           |                          |
| Male                                          | 8 (67%)                  |
| Female                                        | 4 (33%)                  |
| Native country                                |                          |
| Russia                                        | 7 (58%)                  |
| United States                                 | 2 (17%)                  |
| Ukraine                                       | 2 (17%)                  |
| Kazakhstan                                    | 1 (8%)                   |
| Comorbidity                                   |                          |
| Yes                                           | 4 (33%)                  |
| No                                            | 8 (67%)                  |
| Previous abdominal surgery                    |                          |
| Yes                                           | 5 (42%)                  |
| No                                            | 7 (58%)                  |
| ASA grade                                     |                          |
| I                                             | 3 (25%)                  |
| II                                            | 7 (58%)                  |
| III                                           | 2 (17%)                  |
| Surgical approach                             |                          |
| Open                                          | 6 (50%)                  |
| Laparoscopy                                    | 1 (8%)                   |
| Robot                                         | 5 (42%)                  |
| Type of procedure                             |                          |
| Distal gastrectomy                            | 4 (19%)                  |
| Total gastrectomy                             | 7 (58%)                  |
| Completion total gastrectomy                  | 1 (8%)                   |
| Reconstruction                                |                          |
| Billroth-I                                     | 1 (8%)                   |
| Billroth-II                                   | 2 (17%)                  |
| Roux-en-Y                                     | 9 (75%)                  |
| Extent of lymphadenectomy                     |                          |
| D2                                            | 9 (75%)                  |
| D1+                                           | 3 (25%)                  |
| Combined resection                            |                          |
| Yes                                           | 4 (33%)                  |
| No                                            | 8 (67%)                  |
| Operative time (median, range) (min)          | 266 (120–586)            |
| Estimated blood loss (median, range) (mL)     | 90 (37–350)              |
| Retrieved lymph nodes (median, range)         | 37.5 (22–63)             |
| Transfusion                                   |                          |
| Yes                                           | 0 (0%)                   |
| No                                            | 12 (100%)                |
| Postoperative hospital stay (median, range) (days) | 8 (5–63)              |
| Mortality                                     | 0 (0%)                   |
| Morbidity                                     | Total                    | 2 (17%)                 |
| Major (≥grade IIIa*)                          | 2 (17%)                  |

BMI, body mass index; ASA, American Society of Anesthesiologists. *Clavien-Dindo classification.
The results of this case series suggest that morbidity and mortality rates in CPs undergoing gastrectomy with lymphadenectomy may be reduced if performed by experienced surgeons. According to the US Graduate Medical Education General Surgery Report (2012), current graduates performed 3.4 partial gastrectomies and 0.9 total gastrectomies during 5-year training programs. It is well known that mortality rates of high-volume hospitals are lower than those of hospitals where surgeons have less exposure to procedures. One potential strategy to overcome this shortcoming is the centralization of GC patients to specific centers, enabling surgeons to boost their experience through intensive short-term training.

On the other hand, morbidity and mortality rates of the present series seemed to be slightly higher than those of prior East Asian studies where East Asian patients were exclusively enrolled. Additionally, in our previous article, which included 5839 Korean patients between 2005 and 2010, overall-complication, major-complication (Clavien-Dindo classification IIIa or greater), and mortality rates were 10.5% (612 of 5839), 5.8% (337 of 5839), and 0.4% (25 of 5839), respectively. This implies that surgical expertise is not the sole factor in observed morbidity and mortality differences of East Asian and Western countries. Patient-related factors are critical as well. Western patients tend to be more obese than East Asian patients, and obesity typically raises the risk of complications. Anteroposterior girth in Western patients is often sizeable, creating a deep operative field that makes procedures more demanding. Furthermore, obese patients are prone to multiple comorbidities, such as cardiovascular disease and diabetes, which arguably increase morbidity and mortality.

Table 2. Clinicopathological Characteristics of Each Patient

| Patient | Age | Gender | Native country | BMI | ASAG | Comorbidity | PAS | T | N | Stage | Histology |
|---------|-----|--------|----------------|-----|------|-------------|-----|----|---|-------|-----------|
| 1       | 47  | M      | USA            | 45.9| II   | Seizure     | Liposuction | pT1b| pN1| IB  | Poor diff. |
| 2       | 63  | M      | Kazakhstan     | 22.5| I    | None        | None         | pT4a| pN3| IIC | Poor diff. |
| 3       | 71  | M      | Ukraine        | 24.5| II   | None        | None         | pT1b| pN0| IA  | Moderate diff. |
| 4       | 53  | M      | Russia         | 33.6| III  | Hypertension| None         | pT2 | pN0| IB  | Poor diff. |
| 5       | 62  | M      | Russia         | 24.7| II   | None        | None         | pT2 | pN2| IIB | Moderate diff. |
| 6       | 61  | M      | Ukraine        | 28.4| III  | None        | STG          | pT3 | pN3| IIB | Signet ring cell |
| 7       | 42  | M      | Russia         | 19.8| I    | None        | None         | pT4a| pN3| IIC | Poor diff. |
| 8       | 66  | F      | Russia         | 23.2| II   | Hypertension| Appendectomy, cholecystectomy | pT3 | pN2| IIA | Moderate diff. |
| 9       | 65  | M      | Russia         | 18.6| II   | None        | None         | pT4b| pN3| IIC | Poor diff. |
| 10      | 40  | F      | USA            | 18.6| II   | None        | D&C          | pT4a| pN3| IV  | Poor diff. |
| 11      | 67  | F      | Russia         | 26.7| I    | None        | TAH          | pT4a| pN0| IIB | Signet ring cell |
| 12      | 67  | F      | Russia         | 37.6| II   | Hypertension| None         | pT1b| pN1| IB  | Poor diff. |

BMI, body mass index; ASAG, American Society of Anesthesiologists grade; PAS, previous abdominal surgery; T, tumor depth; N, lymph node classification; M, male; F, female; USA, United States of America; STG, subtotal gastrectomy; D&C, dilatation and curettage; TAH, total abdominal hysterectomy; diff., differentiation.

Table 3. Perioperative Results of Each Patient

| Patient | Approach | Type of procedure | ELD | CR | OT (min) | EBL (mL) | RLNC | Complication | PHS (days) |
|---------|----------|-------------------|-----|----|----------|----------|------|--------------|------------|
| 1       | Robot    | TG-RY             | D2  | None | 586      | 350      | 33   | Leak (IIla)* | 29         |
| 2       | Robot    | TG-RY             | D2  | None | 300      | 65       | 46   | Leak (IIla)* | 63         |
| 3       | Open     | DG-RY             | D2  | None | 134      | 40       | 23   | None         | 9          |
| 4       | Robot    | TG-RY             | D1+, 8a, 9, 11p, 12a | None | 291      | 80       | 30   | None         | 8          |
| 5       | Laparoscopy | TG-RY           | D2  | None | 411      | 100      | 63   | None         | 8          |
| 6       | Open     | CTG-RY            | D2  | None | 276      | 300      | 22   | None         | 8          |
| 7       | Robot    | DG-BII            | D2  | Gallbladder | 310    | 100      | 36   | None         | 5          |
| 8       | Open     | DG-BI             | D2  | Thyroid | 120      | 37       | 40   | None         | 7          |
| 9       | Open     | TG-RY             | D1+, 8a, 9, 11p, 11d, 12a | Colon | 257      | 250      | 33   | None         | 9          |
| 10      | Open     | TG-RY             | D2  | None | 128      | 50       | 39   | None         | 5          |
| 11      | Open     | TG-RY             | D2  | None | 150      | 250      | 43   | None         | 8          |
| 12      | Robot    | DG-BII            | D1+, 8a, 9 | Thymus | 216    | 35       | 42   | None         | 5          |

ELD, extent of lymphadenectomy; CR, combined resection; OT, operative time; EBL, estimated blood loss; RLNC, retrieved lymph node count; PHS, postoperative hospital stay; TG, total gastrectomy; DG, distal gastrectomy; CTG, completion total gastrectomy; RY, Roux-en-Y reconstruction; BI, Billroth I reconstruction; Bill, Billroth II reconstruction.

*Clavien-Dindo classification.
present article, Patient 2 was of normal weight, whereas Patient 1 was an extremely obese and visibly high-risk patient, the likes of which are seldom seen in East Asian countries. It is thus easy to appreciate why morbidity and mortality increase when such patients are surgically treated, thus underscoring that patient factors cannot be ignored in this setting.

The present case series had two major limitations. First, the number of patients analyzed was clearly insufficient for conclusive results. We merely showed a possibility of achieving our procedure in CPs with less morbidity and mortality, and it is impossible to draw any further conclusions. Second, we focused only on short-term outcomes. Further investigations involving large numbers of patients and long-term monitoring are needed to confirm the feasibility, safety, and efficacy of standard East Asian surgery of GC, and such studies may elucidate the unique risk factors for complications in CPs who were treated by East Asian surgeons.

In conclusion, although patient-related factors are crucial and cannot be ignored, acceptably low mortality and morbidity rates were achieved in CPs when gastrectomy with lymphadenectomy was performed by experienced East Asian surgeons. Provided that experienced surgeons perform gastrectomy with lymphadenectomy in CPs, there is a possibility that the East Asian approach is feasible and safe.

REFERENCES

1. Noguchi M, Miyazaki I. Prognostic significance and surgical management of lymph node metastasis in gastric cancer. Br J Surg 1996; 83:156-61.
2. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002;195:655-64.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. New York: Springer; 2010.
4. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113-23.
5. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-13.
6. Papenfuss WA, Kukar M, Oxenberg J, Atwood K, Nurkin S, Malhotra U, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol 2014;21:3008-14.
7. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010;251:640-6.
8. Chen Y, Haveman JW, Apostolou C, Chang DK, Mertens ND. Asian gastric cancer patients show superior survival: the experiences of a single Australian center. Gastric Cancer 2015;18:256-61.
9. Gill S, Shah A, Le N, Cook EE, Yoshida EM. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol 2003;21: 2070-6.
10. Bartlett EK, Roses RE, Kelz RR, Drebina JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery 2014;156: 298-304.
11. Grossmann EM, Longo WE, Virgo KS, Johnson FE, Oprian CA, Henderson W, et al. Morbidity and mortality of gastrectomy for cancer in Department of Veterans Affairs Medical Centers. Surgery 2002;131:484-90.
12. Accreditation Council for Graduate Medical Education. General surgery case logs. Updated 2012. Available at: http://www.acgme.org/acgmeweb/Portals/0/GSNatData1112.pdf.
13. Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002;131:6-15.
14. Begg CB, Cramer LD, Hoskins WL, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280:1747-51.
15. Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective referral to high-volume hospitals: estimating potentially avoidable deaths. JAMA 2000;283:1159-66.
16. Lee KG, Lee HJ, Yang JY, Oh SY, Bard S, Suh YS, et al. Risk factors associated with complication following gastrectomy for gastric cancer: retrospective analysis of prospectively collected data based on the Clavien-Dindo system. J Gastrointest Surg 2014;18: 1269-77.
17. Lee JH, Park do J, Kim HH, Lee HJ, Yang HK. Comparison of complications after laparoscopy-assisted distal gastrectomy and open distal gastrectomy for gastric cancer using the Clavien-Dindo classification. Surg Endosc 2012;26:1287-95.
18. Inagawa S, Adachi S, Oda T, Kawamoto T, Koike N, Fukao K. Effect of fat volume on postoperative complications and survival rate after D2 dissection for gastric cancer. Gastric Cancer 2000;3:141-4.
19. Kodera Y, Sasako M, Yamamoto S, Sano T, Nakao A, Kurita A; Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 2005;92:1103-9.
20. Kulig J, Sierzeja M, Kolodziejczyk P, Dadan J, Drews M, Fraczek M, et al. Implications of overweight in gastric cancer: a multicenter study in a Western patient population. Eur J Surg Oncol 2010;36: 969-76.